Lumida
/TMCI
⌘K
Treace Medical Concepts Inc

Treace Medical Concepts Inc

TMCI
$4.72USD+0.32%+0.01 today

MARKET CAP

305.7M

P/E (TTM)

FWD P/E

DAY RANGE

$5 – $5

52W RANGE

$1
$8

AI Summary

Stalk
StalkMedium

TMCI remains in a speculative-stage uptrend but has rolled over below the 9- and 20-day EMAs, marking a corrective phase toward the 50-day SMA support. Medium-term bias stays bullish under Stage 2 permission, yet short-term timing is unfavorable as EMAs turn down. Under a speculative mandate, visible absorption at the support confluence around the 50-day SMA and trendline is required before entry. Stalk pullbacks into that area and await clear buying evidence.

  • Case volumes up high-single-digits sequentially for new bunion systems
  • Full-year 2026 revenue guidance increased to $204M–$212M
  • Q2 revenue fell 4% YoY to $45.4M, signifying top-line pressure
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$94.4M$141.8M$187.1M$209.4M$212.7M
YoY %+50.2%+31.9%+11.9%+1.6%
P / Sales9.6x8.7x4.1x2.2x0.7x
EV / Sales8.9x9.3x4.6x2.7x1.2x
Gross Profit, Adj.$77.5M$116.3M$151.9M$168.3M$169.8M
YoY %+50.0%+30.6%+10.7%+0.9%
Margin %82.1%82.0%81.2%80.4%79.8%
EV / Gross Profit10.9x11.3x5.7x3.3x1.5x
EBITDA, Adj.$-15.8M$-34.8M$-46.1M$-47.3M$-43.5M
YoY %-120.2%-32.2%-2.6%+7.9%
Margin %-16.8%-24.6%-24.6%-22.6%-20.5%
EV / EBITDA-53.4x-37.8x-18.8x-11.7x-5.7x
EBIT$-16.5M$-34.8M$-51.4M$-55.7M$-54.2M
YoY %-111.1%-47.6%-8.3%+2.8%
Margin %-17.5%-24.6%-27.5%-26.6%-25.5%
EV / EBIT-51.1x-37.8x-16.8x-10.0x-4.6x
Net Income$-20.7M$-42.8M$-49.5M$-55.7M$-59.0M
YoY %-106.4%-15.7%-12.6%-5.8%
Net Margin-22.0%-30.2%-26.5%-26.6%-27.7%
EPS (GAAP)-$0.43-$0.77-$0.81-$0.90-$0.93
YoY %-79.1%-5.2%-11.1%-3.3%